*To be consumed as directed by physician.
Composition:
Romiplostim Injection r-DNA Origin (250mcg/vial)
Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Romiplostim 250mcg is administered as a subcutaneous injection. This injection is given to you by the doctor or a nurse in a hospital.
Romiplostim therapy is administered to achieve and maintain a platelet count ≥ 50 × 109/L as necessary to reduce the risk for bleeding. Platelet counts and CBCs must be performed weekly until a stable Romiplostim dose has been achieved; thereafter, platelet counts and CBCs must be performed monthly while taking Romiplostim.
You should inform your doctor regarding any specific allergies you have or if you are on any other medications.
In adult patients, the most common adverse reactions experienced are arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia. In pediatric patients, the most common adverse reactions experienced are- contusion, upper respiratory tract infection, and oropharyngeal pain.
*To be consumed as directed by physician.
Romiplostim is used to treat :
